The Online Investor
Aratana Therapeutics, Inc (PETX)

Aratana Therapeutics is a pet therapeutics company that licenses, develops and commercializes therapeutics for dogs and cats. At Dec 31 2017, Co.'s portfolio included multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and molecule biologics. Co. has three U.S. Food and Drug Administration approved therapeutics: GALLIPRANT® (grapiprant tablets) for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE® (capromorelin oral solution) for appetite stimulation in dogs; and NOCITA® (bupivacaine liposome injectable suspension) as a local post-operative analgesia for cranial cruciate ligament surgery in dogs.
Company Name: 
Aratana Therapeutics, Inc
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree PETX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Aratana Therapeutics, Inc (PETX) Page | The Online Investor Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.